Horizon Pharma, Perrigo deal
Horizon granted Perrigo non-exclusive rights to commercialize a generic version of Pennsaid 2% diclofenac to treat pain associated with osteoarthritis of the knee in the U.S. beginning on Jan. 10, 2029, or earlier under certain circumstances. According to Horizon’s most recent 10-Q, such circumstances may relate to the resolution of other third-party Pennsaid 2% patent litigation, launch of other third-party generic versions or substantial reductions in Horizon’s Pennsaid 2% shipments. The deal settles suits Horizon filed in the U.S. District Court for the District of New Jersey and the U.S. District Court for the District of Delaware relating to Perrigo’s ANDA submission for a Pennsaid 2% generic. Horizon said there were no financial terms. ...